1058702-83-2Relevant articles and documents
COMPOUNDS AND USES THEREOF
-
Page/Page column 114, (2020/08/13)
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS
-
Paragraph 0221; 0222; 0223, (2013/03/26)
The present invention relates to compounds having general formula I characterised in that wherein in particular: R1 represents one or a plurality of groups such as: trifluoromethyl, halogen such as F, Cl, Br, methyl, nitro. R represents nitroge
Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors
Liu, Gang,Lynch, John K.,Freeman, Jennifer,Liu, Bo,Xin, Zhili,Zhao, Hongyu,Serby, Michael D.,Kym, Philip R.,Suhar, Tom S.,Smith, Harriet T.,Cao, Ning,Yang, Ruojing,Janis, Rich S.,Krauser, Joel A.,Cepa, Steven P.,Beno, David W. A.,Sham, Hing L.,Collins, Christine A.,Surowy, Teresa K.,Camp, Heidi S.
, p. 3086 - 3100 (2008/02/10)
Stearoyl-CoA desaturase 1 (SCD1) catalyzes the committed step in the biosynthesis of monounsaturated fatty acids from saturated, long-chain fatty acids. Studies with SCD1 knockout mice have established that these animals are lean and protected from leptin